Goldman Sachs says buy this biotech stock with more than 60% upside

[Pelican Press 0]

Goldman Sachs says buy this biotech stock with more than 60% upside

This is the hidden content, please

• Sign In
• or
• Sign Up

.” Indeed, investors have grown concerned over Jazz’s potential loss of exclusivity and rising competition regarding oxybates, which reduces daytime sleepiness. But Tan cited the company’s “overlooked” pipeline as a potential offset for these expected losses. “We believe JAZZ is entering a ******* of growth from its late-stage pipeline, with upcoming catalysts serving as value inflection points for the name across oncology,” she wrote. An additional catalyst comes in the form of Vision 2025, Jazz’s strategic initiative launched in January 2022 to target $5 billion in revenue from 2025. Taking recent sales and near-term catalysts into consideration, the analyst wrote that she sees Vision 2025 as achievable. Jazz’s balance sheet also looks strong, and the company has demonstrated a consistent history of cash generation, according to the analyst. Tan believes that this bodes well for the company’s future investments in external innovation through mergers and acquisitions or business development.

This is the hidden content, please

• Sign In
• or
• Sign Up

Under the Radar,Jazz Pharmaceuticals PLC,Stock markets,Investment strategy,business news
#Goldman #Sachs #buy #biotech #stock #upside

This is the hidden content, please

• Sign In
• or
• Sign Up